Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Glaucoma, Glaucoma

When Multiple Punctures Don’t Deflate

It’s now acknowledged that intravitreal injections of anti-VEGF agents do carry a small risk of increasing patients’ IOP – sometimes transiently, sometimes sustained. Many patients receive these injections monthly, so the question is: how serious can it get? To find out, a team of Vancouver-based ophthalmologists and researchers got on the case (1).

The team had access to large, linked, population-based heath databases (supported by the British Columbia Ministry of Health) and searched for all patients with ophthalmic issues that had received intravitreous bevacizumab for exudative AMD during the years of 2009–2013. Next, they identified a subset of interesting records – ones that contained glaucoma surgical codes for trabeculectomy, complicated trabeculectomy, glaucoma drainage devices, and cycloablative procedures (n=74). Ten controls were identified for each of the 74 cases and matched for age, prexisting conditions, calendar time, and follow-up time for each case (n=740). Both cases and controls were stratified by the number of bevacizumab injections received per year: ≤3, 4–6, and ≥7.

Figure 1. a. Number of number of intravitreous bevacizumab injections per year; b. Adjusted rate ratios for glaucoma surgery stratified by the number of bevacizumab injections received per year. All data were normalized to the ≤3 injections per year group.

After adjusting for comorbidities, the proportion of patients who received ≥7 injections per year was 10.3 percent greater than the proportion in the control group (44.6 vs. 34.3 percent; Figure 1a). For the case-control analysis, patients who received three or fewer injections per year served as the reference category; here, the adjusted rate ratio (RR) of glaucoma surgery among those who received seven or more injections per year was 2.48 (95% CI, 1.25–4.93), with the RR for patients receiving 3–6 injections per year being 1.65 (0.84–3.23; Figure 1b).

In an accompanying editorial, Apte et al. (2) noted, “most patients who receive intravitreous anti-VEGF injections do not develop ocular hypertension or glaucoma.” However, the authors also stated that it was “prudent to observe all patients receiving intravitreous anti-VEGF injections for evidence of elevated IOP and glaucoma” and that such observation was “especially important for those patients with preexisting ocular hypertension or glaucoma.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. BD Eadie et al., “Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery”, JAMA Ophthalmology, [Epub ahead of print] (2016). PMID: 28301639.
  2. RS Apte et al., “Anti-VEGF injections and glaucoma surgery”, JAMA Ophthalmology, [Epub ahead of print] (2016). PMID: 28301640.
About the Author
Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Related Case Study
Finding Ocular Surface Inflammation

| Contributed by Quidel

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register